Latest News
In this section you will find the latest Bayer Schering Pharma press releases for the United Kingdom.
If you have a particular enquiry about any of these releases then please contact us on the telephone number or e-mail address below:-
Tel: 01635 563198
E-mail: bsp-communications@bayerhealthcare.com
Avelox® (Moxifloxacin) IV Granted UK Licence for the Treatment of Community-Acquired Pneumonia and Complicated Skin and Skin Structure Infections
10th March 2010
Newbury, Berkshire, 10th March 2010 – Bayer Schering Pharma is pleased to announce that Avelox® IV (moxifloxacin HCl, solution for infusion) is now available in the UK for the treatment of Community-Acquired Pneumonia (CAP) and complicated Skin and Skin Structure Infections (cSSSI) when antibacterial agents that are commonly recommended for the initial treatment of these infections are considered inappropriate.1
>>more
Final chance for liver cancer patients
22nd February 2010
NICE to hear Bayer’s appeal on the Institute’s decision not to recommend NHS funding for Nexavar® in patients with the most common primary liver cancer.
>>more
NICE recommends all patients admitted to hospital are risk assessed for VTE
27th January 2010
Publication of today’s National Institute for Health and Clinical Excellence’s (NICE) updated Clinical Practice Guideline for prevention of Venous Thromboembolism (VTE) recommends that, for the first time, all patients admitted to hospital are risk assessed for VTE and appropriate measures taken.
>>more